Posted by Noah T. Ditto

Rapid deployment of antibody discovery technologies capable of high-throughput and high-resolution screening is imperative for the timely development of therapeutics for global pandemics. Risk mitigation using multiple advanced technologies further increases the likelihood of identifying efficacious treatments in an aggressive timeline. In the first part of this webinar, Colby Souders, CSO of Abveris, will discuss the following:

  • An integrated in vivo approach incorporating two parallel workflows for accelerated discovery of lead antibody candidates targeting the SARS-CoV-2 spike protein
  • A single B-cell discovery workflow to directly interrogate antibodies secreted from plasma cells of human transgenic Alloy-GK mice and Abveris’s proprietary DiversimAb mouse for binding specificity and ACE2 receptor blocking activity
  • A concurrent accelerated hybridoma-based workflow utilizing the DiversimAb mouse model for increased diversity
  • Advanced high-throughput and high-content characterization of antibodies with the Carterra LSA in two assay formats (purified and crude samples) to rapidly determine binding affinity, blocking profiles, and epitopic coverage for lead candidate identification

The Carterra LSA is transforming the landscape of drug discovery and has now become an indispensable tool for cutting-edge research teams like Abveris. In the second part of the webinar, Noah T. Ditto, Technology Product Manager at Carterra, will provide an introduction to what makes the LSA critical for effective and modern drug discovery workflows:

  • Orders of magnitude more data than traditional platforms per experiment
  • Extremely low reagent requirements
  • Minimal hands-on time and unattended run times of up to a week
  • Characterization campaigns for hundreds of clones completed in just days